Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosimetry-based versus standard-dose PRRT with Lu-177-DOTATOC in neuroendocrine neoplasm patients
2019-002450-23Phase 2Active
- Sponsor
- Anne Kirstine Arveschoug
- Start
- Aug 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised trial of lutetium Lu 177-edotreotide in apudoma (NET), gastrointestinal neuroendocrine neoplasm (GI-NEN), islet cell tumor and 2 more (2 arms), sponsored by Anne Kirstine Arveschoug. Primary endpoint: Progression-free survival. Started Aug 2019; status: active.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
apudoma (NET)gastrointestinal neuroendocrine neoplasm (GI-NEN)islet cell tumorpheochromocytomabronchial neuroendocrine tumor
Beyond the preview
Go deeper on 2019-002450-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002450-23.